The mode of action of actinomycin D. 1960

J M KIRK

UI MeSH Term Description Entries
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J M KIRK
January 1962, Biochemical pharmacology,
J M KIRK
July 1965, Science (New York, N.Y.),
J M KIRK
August 1964, Biochimica et biophysica acta,
J M KIRK
January 2005, Postepy higieny i medycyny doswiadczalnej (Online),
J M KIRK
March 1968, Revue francaise d'etudes cliniques et biologiques,
J M KIRK
January 1967, Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie,
J M KIRK
August 1961, The Journal of experimental zoology,
J M KIRK
September 1965, Die Naturwissenschaften,
J M KIRK
February 1963, Comptes rendus hebdomadaires des seances de l'Academie des sciences,
Copied contents to your clipboard!